In the era of meager profit, a large number of generic drugs have been stopped research and development!

[industry trends of pharmaceutical network] according to public data, as of the end of November 2017, there were 4376 API and preparation manufacturing enterprises in China, of which more than 90% were generic enterprises; nearly 170000 drug batch numbers, of which more than 95% were generic Among thousands of generic pharmaceutical enterprises, only a few are in the transition stage from imitation to innovation Recently, the author learned that because of the fierce competition of generic drugs, especially after the reform of the national review and approval system, there are more approvals and slower access after listing; therefore, in the summer of last year, Hengrui has stopped general generic drug projects and only made innovative drugs and generic drugs with core value In the era of Counterfeiting Drugs welcoming low profit, some industry figures say that counterfeiting drugs account for 90% of China's pharmaceutical market In 2016, the market scale of generic drugs is close to 1 trillion yuan, and it is expected to reach 1.4 trillion yuan by 2020 In recent years, with the acceleration of the review and approval of new drugs in China, the promotion of "4 + 7" pilot centralized procurement, the dynamic adjustment of medical insurance catalog, and the adoption of the new drug administration law, the competition of generic drugs has undergone qualitative changes, and China's generic drugs may face the risk of collective price reduction In fact, as early as the implementation of the consistency evaluation policy for generic drugs, some pharmaceutical industry analysts have asserted that at least 3000 of China's more than 4000 pharmaceutical manufacturers will be eliminated under the pressure of reduced profits and upgraded quality However, under the double-sided attack of improving quality and reducing price in volume purchasing, this process may accelerate to come In the future, the profits of generic pharmaceutical market may be concentrated in the hands of three or four giants In the past, the main test of the competition among generic pharmaceutical enterprises was the ability of pharmaceutical enterprises to follow up the original research drugs and make imitations If pharmaceutical enterprises can make imitations first and cooperate with excellent sales ability, it is easy to occupy the market, and the quality of drugs is not a priority Now, including in the future, with the promotion of the 4 + 7 pilot, quality has become the threshold to be prioritized, while cost control ability and production capacity have become the key to win However, affected by the volume purchase, many generic drugs have declined too much, which leads to the market entering the era of low profit, and the low profit may make more enterprises choose to give up the production of generic drugs Innovation and R & D into industry trend: on the premise of 4 + 7 and consistency evaluation, some enterprises think that it is better to increase R & D investment and change the track to take the road of innovation than to jam with most pharmaceutical enterprises on narrow track For example, in recent years, Hengrui pharmaceutical has been continuously investing in research and development Sun piaoyang, chairman of Hengrui pharmaceutical, said in a public statement recently that up to now, the original research drug expired in the market has been copied by Hengrui pharmaceutical Even if there is a long time to maturity, its market value is not high after evaluation Therefore, from the perspective of input-output ratio, Hengrui believes that the investment value is not too large and decides to invest in more effective innovative drug research and development At a time when the country pays more and more attention to innovative drugs and gradually promotes the consistency evaluation of generic drugs, biomedical enterprises pay more and more attention to R & D innovation, which can be seen from the R & D cost investment of major pharmaceutical enterprises According to the R & D investment in the first half of 2019 of 232 pharmaceutical listed companies released by an institution, the domestic pharmaceutical companies with high and steady R & D investment include Hengrui, China biopharmaceutical, Fosun Pharmaceutical, Haizheng pharmaceutical, etc According to the report of Hengrui in the first half of the year, its operating revenue in the first half of the year was 10.026 billion yuan, an increase of 29.19% over the same period of last year; the net profit attributable to shareholders of listed companies was 2.412 billion yuan, an increase of 26.32% over the same period of last year; the total operating cost was 377195.24, and the R & D investment reached 1484.1152 million yuan This year, its R & D expenditure is expected to exceed 3 billion yuan At present, it has approved the listing of five innovative drugs, which also plays a key role in promoting the revenue growth of the whole company China's biopharmaceutical business covers the whole industrial chain of various pharmaceutical R & D platforms, intelligent production and strong sales system The company has accumulated 497 in-process products with clinical approval documents, ongoing clinical trials and application for production Among them, 206 anti-tumor drugs, 54 cardiovascular and cerebrovascular drugs, 38 liver drugs, 25 respiratory drugs, 26 diabetes drugs and 148 other drugs were used In addition, according to the 2019 semi annual report released by Fosun Pharmaceutical, the operating revenue reached 14.173 billion yuan, an increase of 19.51% compared with the same period in 2018, and the operating revenue increased by 19.36% compared with the same caliber in the same period in 2018 The cumulative R & D investment was 1.351 billion yuan, up 13.69% year on year Among them, R & D investment in pharmaceutical business was 1.205 billion yuan, up 13.23% year on year, accounting for 11.1% of pharmaceutical business revenue Compared with other innovative pharmaceutical enterprises horizontally, more than 10% of R & D revenue has been in the echelon of top pharmaceutical enterprises With the irreversible trend of generic medicine towards the era of meager profit, most pharmaceutical companies have to start to plan for the future What can generic pharmaceutical companies do? Some insiders said that at present, most pharmaceutical enterprises in China have not been able to do new drug research and development They should be honest to do a good job in generic drugs, or strive for generic drugs After all, China's generic drug market is still very large Moreover, we should not innovate for the sake of innovation In fact, to meet the new clinical needs is innovation, including the change of dosage form and the change of drug delivery route Although the way of innovation is the way for pharmaceutical enterprises to become a more competitive enterprise, don't worry The development from imitated medicine to innovative medicine can not be achieved overnight We should combine our own conditions and go step by step.